Testing is underway on vaccines to intercept brewing colon cancer before it takes root

Dr. Stacy Norton, who was seven years old when her mother passed away from colon cancer, is among the estimated one million Americans who have Lynch syndrome. This genetic condition, inherited from a parent, significantly increases the risk of colorectal cancer and other cancers as well. Often, individuals with Lynch syndrome are advised to undergo frequent colonoscopies to detect and remove precancerous growths known as polyps.

Scientists are developing vaccines that could potentially intercept the development of colon cancer, teaching the immune system to identify and combat the disease before it progresses to a full-blown tumor. Three potential Lynch syndrome vaccines are currently under development, including two in early clinical trials in the U.S. and a third starting in Britain.

Dr. Eduardo Vilar-Sanchez, the lead researcher at the MD Anderson Cancer Center, is optimistic about one of these vaccines, anticipating a larger study to commence early next year.

Norton, currently 59 years old, participated in a trial of one of these vaccines. She shared that this development provides her with hope, as a successful vaccine could potentially eliminate the need for yearly colonoscopies for her and her two children, who also inherited her Lynch syndrome mutation. Lynch syndrome is characterized by an inherited genetic mutation that impairs the body's ability to repair errors in DNA during cell division.

This results in a higher likelihood of developing tumors, often before the age of 50. While the general population has a 5% risk of developing colorectal cancer at some point in their lives, for those with Lynch syndrome, this risk can escalate to as high as 80%, depending on the specific gene mutation involved.